Kanada - Inggeris - Health Canada

rheingold food international ltd. - calcium (calcium carbonate); magnesium (magnesium oxide); zinc (zinc oxide); vitamin d2 - capsule - 333.33mg; 166.67mg; 6mg; 100unit - calcium (calcium carbonate) 333.33mg; magnesium (magnesium oxide) 166.67mg; zinc (zinc oxide) 6mg; vitamin d2 100unit - vitamins & minerals

Kanada - Inggeris - Health Canada

holista health (canada) inc. - calcium (calcium citrate); magnesium (magnesium oxide); potassium (potassium citrate); zinc (zinc citrate); vitamin d3 - capsule - 125mg; 125mg; 10mg; 5mg; 100unit - calcium (calcium citrate) 125mg; magnesium (magnesium oxide) 125mg; potassium (potassium citrate) 10mg; zinc (zinc citrate) 5mg; vitamin d3 100unit - vitamins & minerals

Kanada - Inggeris - Health Canada

health-wise nutrition inc. - calcium (calcium carbonate, calcium hvp chelate); magnesium (magnesium oxide, magnesium hvp chelate); zinc (zinc hvp chelate, zinc citrate); ascorbic acid; vitamin d - tablet - 350mg; 175mg; 10mg; 25mg; 200unit - calcium (calcium carbonate, calcium hvp chelate) 350mg; magnesium (magnesium oxide, magnesium hvp chelate) 175mg; zinc (zinc hvp chelate, zinc citrate) 10mg; ascorbic acid 25mg; vitamin d 200unit - vitamins & minerals

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sandoz inc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 5 mg in 1 ml

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin  injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-sus

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin  injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-sus

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin  injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-sus

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sagent pharmaceuticals - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 25 mg in 1 ml

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

h & r healthcare ltd -

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

h & r healthcare ltd -